- Home
- CURV vs ELTX Comparison
CURV vs ELTX Comparison
Compare CURV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | ELTX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 185.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CURV | ELTX |
|---|---|---|
| Price | $2.48 | $3.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $1.59 | ★ $18.00 |
| AVG Volume (30 Days) | 305.7K | ★ 1.1M |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.94 | $2.66 |
| 52 Week High | $2.72 | $16.00 |
Technical Indicators
Market Signals| Indicator | CURV | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.63 | 35.97 |
| Support Level | $1.01 | $2.72 |
| Resistance Level | N/A | $9.62 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | 0.04 | 0.25 |
| Stochastic Oscillator | 89.17 | 28.33 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.